Skip to content

Citius Oncology, Inc. CTOR Common Stock Par Value Per Share

Common Stock Par Value Per Share at other companies

Delcath Systems logo
Delcath SystemsDCTH
$0.010.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$0.000.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$0.000.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$0.000.0%

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s common stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s common stock par value per share?
Citius Oncology, Inc. (CTOR) reported common stock par value per share of $0.00 in Q1 2026.
How has Citius Oncology, Inc.'s common stock par value per share changed year-over-year?
Citius Oncology, Inc.'s common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
What is the long-term trend for Citius Oncology, Inc.'s common stock par value per share?
Over 3 years (2022 to 2025), Citius Oncology, Inc.'s common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
What does common stock par value per share mean?
The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.